Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of PEGylated Doxorubicin Hydrochloride Liposome Injection(Duomeisu®) Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer: A Randomized, Open, Multicenter Clinical Study

NCT03794778 is registered in ClinicalTrials.gov with Women's Hospital School Of Medicine Zhejiang University as lead sponsor.

NCT NCT03794778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03794778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of PEGylated Doxorubicin Hydrochloride Liposome Injection(Duomeisu®) Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer: A Randomized, Open, Multicenter Clinical Study
Lead sponsor
Women's Hospital School Of Medicine Zhejiang University
Phase
Phase 4
Overall status
Unknown status
Start date
March 19, 2019
Completion date
March 31, 2024
Enrollment
396 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy and safety